Scientific Sense ®

COVID-19, clinical trial processes, pharmaceutical R&D, vaccine development, use of preventative medications, Alzheimer's disease, PTSD After obtaining his medical degree in Belgium in 1972, Pierre Etienne moved to McGill University, where he did postgraduate work in neurochemistry. There he directed a program on the biochemical, physiological, and neuropathological basis of Alzheimer's disease. After a brief passage in experimental medicine at Ciba-Geigy (now Novartis), he went back to McGill in 1987, dividing his time between the Montreal Neurological Institute and the Allan Memorial Institute. In 1989 he joined Pfizer as Director of Experimental Medicine, responsible for all Phase 2 A programs for US and Japan discovered compounds. In 2003, he became CEO of PhageTech, Inc., a privately-held biotechnology company based in Montreal, Canada. PhageTech exploited a proprietary platform based on phage-bacterial intracellular interactions to research and develop new classes of synthetic antibiotics. Phagetech later became Targanta Therapeutics that went public on NASDAQ (TARG) in the summer of 2008. In December 2009, he started a new life as a physician at the Douglas Institute. In July 2011, he was appointed Director of the Clinical Research Division. He is the co-Director of the Alzheimer’s disease prevention program (Stop-AD).